QuANTUM-First Trial: FMS-like Tyrosine Kinase 3-Internal Tandem Duplication (FLT3-ITD)-Specific Measurable Residual Disease (MRD) Clearance Assessed Through Induction and Consolidation Is Associated with Improved Overall Survival (OS) in Newly Diagnosed (ND) FLT3-ITD+ AML Patients
Publication
, Conference
Perl, AE; Erba, HP; Montesinos, P; Vrhovac, R; Patkowska, E; Kim, H-J; Zak, P; Wang, P-N; Rohrbach, JEC; Chang, KCN; Liu, L; Kamel, YM ...
Published in: CLINICAL LYMPHOMA MYELOMA & LEUKEMIA
2024
Duke Scholars
Published In
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA
EISSN
2152-2669
ISSN
2152-2650
Publication Date
2024
Volume
24
Start / End Page
S298 / S298
Related Subject Headings
- 3211 Oncology and carcinogenesis
- 3201 Cardiovascular medicine and haematology
- 1112 Oncology and Carcinogenesis
- 1103 Clinical Sciences
Citation
APA
Chicago
ICMJE
MLA
NLM
Perl, A. E., Erba, H. P., Montesinos, P., Vrhovac, R., Patkowska, E., Kim, H.-J., … Levis, M. J. (2024). QuANTUM-First Trial: FMS-like Tyrosine Kinase 3-Internal Tandem Duplication (FLT3-ITD)-Specific Measurable Residual Disease (MRD) Clearance Assessed Through Induction and Consolidation Is Associated with Improved Overall Survival (OS) in Newly Diagnosed (ND) FLT3-ITD+ AML Patients. In CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (Vol. 24, pp. S298–S298).
Perl, Alexander E., Harry P. Erba, Pau Montesinos, Radovan Vrhovac, Elzbieta Patkowska, Hee-Je Kim, Pavel Zak, et al. “QuANTUM-First Trial: FMS-like Tyrosine Kinase 3-Internal Tandem Duplication (FLT3-ITD)-Specific Measurable Residual Disease (MRD) Clearance Assessed Through Induction and Consolidation Is Associated with Improved Overall Survival (OS) in Newly Diagnosed (ND) FLT3-ITD+ AML Patients.” In CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 24:S298–S298, 2024.
Perl AE, Erba HP, Montesinos P, Vrhovac R, Patkowska E, Kim H-J, et al. QuANTUM-First Trial: FMS-like Tyrosine Kinase 3-Internal Tandem Duplication (FLT3-ITD)-Specific Measurable Residual Disease (MRD) Clearance Assessed Through Induction and Consolidation Is Associated with Improved Overall Survival (OS) in Newly Diagnosed (ND) FLT3-ITD+ AML Patients. In: CLINICAL LYMPHOMA MYELOMA & LEUKEMIA. 2024. p. S298–S298.
Perl, Alexander E., et al. “QuANTUM-First Trial: FMS-like Tyrosine Kinase 3-Internal Tandem Duplication (FLT3-ITD)-Specific Measurable Residual Disease (MRD) Clearance Assessed Through Induction and Consolidation Is Associated with Improved Overall Survival (OS) in Newly Diagnosed (ND) FLT3-ITD+ AML Patients.” CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, vol. 24, 2024, pp. S298–S298.
Perl AE, Erba HP, Montesinos P, Vrhovac R, Patkowska E, Kim H-J, Zak P, Wang P-N, Rohrbach JEC, Chang KCN, Liu L, Kamel YM, Imadalou K, Lesegretain A, Cortes J, Sekeres MA, Dombret H, Amadori S, Wang J, Schlenk RF, Levis MJ. QuANTUM-First Trial: FMS-like Tyrosine Kinase 3-Internal Tandem Duplication (FLT3-ITD)-Specific Measurable Residual Disease (MRD) Clearance Assessed Through Induction and Consolidation Is Associated with Improved Overall Survival (OS) in Newly Diagnosed (ND) FLT3-ITD+ AML Patients. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA. 2024. p. S298–S298.
Published In
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA
EISSN
2152-2669
ISSN
2152-2650
Publication Date
2024
Volume
24
Start / End Page
S298 / S298
Related Subject Headings
- 3211 Oncology and carcinogenesis
- 3201 Cardiovascular medicine and haematology
- 1112 Oncology and Carcinogenesis
- 1103 Clinical Sciences